Form 4: Macrogenics CEO Scott Koenig Acquires 31,673 Shares of Common Stock Through RSU Vesting
SEC Form 4 Filing
Macrogenics CEO Scott Koenig acquired 31,673 shares of common stock on February 8, 2025, through the vesting of restricted stock units (RSUs).
Summary
- On February 8, 2025, Scott Koenig, the President and CEO of Macrogenics Inc., acquired 31,673 shares of common stock.
- This acquisition resulted from the vesting of restricted stock units (RSUs).
- The price per share was $0 at the time of vesting.
- Following the transaction, Koenig directly owns 735,086 shares of Macrogenics Inc.
- Koenig also holds 63,327 restricted stock units.
- The RSUs convert into common stock on a one-for-one basis.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to executive compensation. The CEO increasing their stake in the company is generally viewed as a positive, but it's part of a pre-planned vesting schedule.
Positives
- The CEO's acquisition of shares through RSU vesting could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The remaining 66% of the initially granted RSUs will vest in two equal installments on February 8, 2026 and February 8, 2027.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This transaction is typical for executives who receive stock-based compensation.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the biotechnology industry to align executive incentives with shareholder value.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize RSUs and stock options as part of their executive compensation packages.
- The vesting schedules and amounts of RSUs granted to executives vary depending on the company's size, performance, and compensation philosophy.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the CEO's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 02/08/2024 | Date the reporting person was granted 95,000 restricted stock units. |
| 02/08/2025 | Date of transaction: 31,673 restricted stock units vested and converted to common stock. |
| 02/11/2025 | Date of signature for the Form 4 filing. |
Keywords
Macrogenics, MGNX, Scott Koenig, CEO, restricted stock units, RSU, Form 4, beneficial ownership, stock acquisition, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.